Analysts at Maxim Group lifted target price for shares of BioPharmX Corporation (NYSE:BPMX) but repeated their Buy recommendation for the stock in their opinion released on September 13. The price target has been raised from $3 to $1.50.
By watching the trading activity of corporate insiders, it will become easier to get a sense of BioPharmX Corporation (NYSE:BPMX)’s prospects. The earliest insider trade took place on 10/22/2018. Morlock Stephen parted with a total of 1.13 million shares of company at average share price of $0.18. The total for the sales was set at $202.5 thousand. After this transaction, the Director account balance stood at 0 thousand shares. The stock lost -33.33 percent since that insider sale. On 10/12/2018, Krammer Anja B, Director, sold 500 thousand shares at a price per share of $0.19. This removed 95 thousand shares from the insider’s fortune and the stock saw a -36.84 percent retreat in value since the news became public. This transaction left 2 million shares in the Director account. On 09/19/2018, CEO Tierney David S performed a purchase transaction worth $20 thousand. This purchase at $0.2 each has added 100 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded -40 percent decrease since the transaction was reported. The insider now is left with 7.5 million shares remaining in the account. Vivo Capital Viii, Llc, who performs the 10% Owner job, sold 2 million shares for $720 thousand. The disposal occurred on 03/07/2018 was priced at $0.36 per share. The share price plunged -66.67 percent since the reporting date. Vivo Capital Viii, Llc now left with a stake of 16.13 million BPMX stock worth $1.94 million after the insider selling.
BioPharmX Corporation (BPMX) is expected to jump by -100 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $1-month high price target. This represents a whopping 733.33 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $0.7, which represents a return potential of 483.33 percent when compared to the closing price of the stock of $0.12 on Friday, January 11. The lowest price target for the stock is $0.4 — slightly more than 233.33 percent from BPMX’s current share price.
The shares are currently floating around the first support level of $0.12. Below this, the next support is placed in the zone of $0.11. Till the time, the BPMX stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 47.14 on daily chart, which may remain a cause for concern. If the price breaks below $0.11 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $0.13 mark may result into a pull-back move towards $0.13 level.
BPMX shares dropped 0 points or -3.87 percent on Friday to $0.12 with a heavy trade volume of 4.508 million shares. After opening the session at $0.13, the shares went as high as $0.13 and as low as $0.12, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $26.47 million and now has 221.85 million shares outstanding. BioPharmX Corporation (BPMX) stock has lost -3.79 percent of market value in 21 trading days.
BPMX stock has a trailing 3-year beta of 0.33, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.04 a share in the trailing twelve months. The stock’s value has surged 10.57 percent year to date (YTD) against a rise of 3.74 percent in 12 month’s time. The company’s shares still trade -68.2 percent away from its 1-year high of $0.38 and 138.6 percent up from 52-week low of $0.05. The average consensus rating on the company is 0, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.
Shares of BioPharmX Corporation (BPMX) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry BPMX operates in has an average P/E of 69.71. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 372.77 on the Price-to-Sales ratio. Compare this with the industry average P/S of 49.51. 0 percent is the gross profit margin for BioPharmX Corporation and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.